T hyroid hormone levels (free thyroxine [FT 4 ] and free triiodothyronine [FT 3 ]) are tightly regulated through feedback inhibition by thyrotropin, produced by the pituitary gland.
1 Thyrotropin is measured clinically to assess thyroid function as it can detect thyroid hormone abnormalities with higher sensitivity and specificity than FT 4 or FT 3 . 1 Overt hyperthyroidism is overwhelmingly due to thyroid disorders including Graves disease, toxic adenoma goiter, or toxic multinodular goiter 1 and is well recognized to contribute to a wide spectrum of morbidity including atrial fibrillation (AF), hypertension, heart failure, and cerebrovascular diseases. 2 Owing to feedback inhibition, hyperthyroidism due to thyroid gland disorders is characterized by low serum thyrotropin levels. 1 Conversely, hypothyroidism is associated with high thyrotropin levels. Thyroid hormone levels are highly heritable, and multiple common single-nucleotide variants (SNVs) have been associated with thyrotropin levels. 3, 4 Longitudinal electronic health record (EHR) data capture diverse clinical outcomes in large sample sizes and, when coupled with large-scale DNA collections, have been used to define the disease spectrum associated with single or multiple genomic variants. 5, 6 We report here a phenome-wide association study (PheWAS) identifying clinical diagnoses associated with a polygenic predictor of thyrotropin levels identified by a previously published genome-wide association study (GWAS) that included North American and European participants. 3 We performed phenomewide scanning of 1318 phenotypes using a cohort of 37 154 North American individuals of European ancestry with EHR data (Table 1) .
7,8

Methods
Study Populations
The primary EHR population was derived from the eMERGE (Electronic Medical Records and Genetics) PhaseI&IINetwork (n = 16 924), a consortium of medical centers using EHRs as a tool for genomic research, and from Vanderbilt University Medical Center's BioVU resource (n = 20 230). 7, 9 We have previously found that this data set performs robustly for biomarkers discovery and validation. 10 The participating eMERGE sites were Geisinger Health System, Vanderbilt University Medical Center, Marshfield Clinic, Northwestern University, Mayo Clinic, and Kaiser Permanente/University of Washington. BioVU is Vanderbilt University Medical Center's deidentified collection of patients whose DNA was extracted from discarded blood and linked to phenotypes through a deidentified EHR. 9 All individuals were born prior to 1990 and fell within 4 SDs for each of the first 2 principal components based on common SNVs for the subset of individuals self-identified as white/non-Hispanic. The eMERGE study was approved by the local institutional review board at each eMERGE site, and participant consent was obtained per institutional review board-approved protocols at each site. 7 Between-site variability in terms of the positive predictive value of phenotyping algorithms (in particular, for hypothyroidism) and replication of published associations between SNVs and clinical phenotypes has been shown to be high and have been published elsewhere. 6, [10] [11] [12] [13] We identified 6797 individuals of European ancestry in BioVU who did not have any International Classification of Diseases, Ninth Revision, or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, codes for thyroid diseases and who had thyrotropin measurements that fell within the clinically normal reference range.
Summary Statistics
Two sets of SNVs previously found to be associated with thyrotropin from 2 independent GWAS studies were used in this study (Table 1) . 3, 4 The international SNVs set (n = 20) was previously identified in 26 420 patients with euthyroid of European ancestry from Europe and North America. 3 This set was used for both discovery PheWAS and the replication inversevariance weighted average (IVWA) meta-analysis. To further confirm replication of our results using IVWA meta-analysis, we also used a second Iceland thyrotropin SNVs set (n = 24) previously identified in 27 758 Icelanders with an insular genetic background. 4 For the discovery PheWAS, we used the European ancestry international rather than the Icelandic thyrotropin SNVs predictor because its extrinsic validity in a North American EHR cohort was, a priori, more suitable considering that approximately 25% of participants were from North America in the international data set.
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Summary statistics for AF were from a prior meta-analysis of 31 GWAS studies performed by the Atrial Fibrillation Genetics (AFGen) consortium.
14 The AFGen consortium is a collaboration among multiple studies with the aim of investigating the genetic causes of AF. Atrial fibrillation cases had either documented AF on an electrocardiogram and/or 1 inpatient or 2 outpatient diagnoses of AF. Controls were free of AF. 14 The majority of the participants were of European ancestry (15 979 cases, 102 776 referents) but also included African American (3 studies; 641 cases, 5234 referents), Japanese (1 study; 837 cases, 3293 referents), Hispanic (1 study; 277 cases, 3081 referents), and Brazilian (1 study; 197 cases, 758 referents) individuals.
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Genetic Data
In the BioVU eMERGE EHR cohort, SNVs genotype data were acquired on the Illumina Human660W-Quadv1_A, HumanOmni1-Quad, HumanOmni5-Quad, MEGA-EX, Human610, Human550, HumanOmniExpressExome-8v1.2A, and Affymetrix 6.0 SNV array platforms. Quality control steps for the EHR data sets were performed per previously published protocols. 15, 16 For each data set, SNVs were prephased using SHAPEIT, 17 version 2.r837 (Oliver Delaneau), and imputed using IMPUTE2, 18 version 2.3.0 (University of Oxford), in conjunction with the October 2014 release of the 1000 Genomes cosmopolitan reference haplotypes. All platforms were imputed to the 1000 Genomes standard, which comprises approximately 80 000 000 common and rare SNVs. Singlenucleotide variants used to construct the thyrotropin predictors were drawn from this data and were imputed on 1 or more platforms. Phenotypes that only affected a single sex (eg, uterine prolapse, prostatitis) were not included in the primary analyses but were examined in secondary analyses. There were 1318 clinical phenotypes with more than 150 cases in the EHR data set that were used in the PheWAS analyses. Controls were individuals without the clinical phenotype or any closely related phecodes (as defined by the phecode) and whose decade of birth fell within the range of birth decades observed among cases. For the phenotype with the smallest number of controls (n = 1098), the study had 80% power to detect an association with an odds ratio (OR) of more than 2.9 for a phenotype with 150 cases (at α=1.89×10 −5 ), assuming a baseline risk of disease of 10%
(power calculation used the Vanderbilt biostatistics power and sample size application, version 3.0).
To determine the validity of the significant PheWAS associations, clinical record review was performed by 2 clinicians (J.D.M. and J.-E.S.) for PheWAS phenotypes representative of hypothyroidism (phecode 427.21), hyperthyroidism/goiter (phecode 242.2), and hypothyroidism (phecode244). For each phenotype, 30 records of BioVU individuals who were cases in the PheWAS analyses were reviewed to determine whether the clinical documentation supported the diagnosis identified by International Classification of Diseases, Ninth Revision, codes. The positive predictive value for each phenotype was then determined.
Among the BioVU individuals with thyrotropin measurements, there were 745 AF cases and 1680 controls based on the PheWAS AF definition and who were older than 55 years. These individuals were used to directly test for an epidemiologic association between thyrotropin measurements within the normal range and AF.
Statistical Analysis
Linear mixed models, as implemented in the program Genomewide Complex Trait Analysis, version 1.26.0, 19 were used to estimate the proportion of the phenotypic variance in thyrotropin levels explained by common SNVs using a subset of individuals with measured thyrotropin and no thyroid disease (n = 6797). 19 The analyses were based on 1 888 974 SNVs with minor allele frequency more than 0.01 and were adjusted for age, sex, and 20 principal components, per standard protocols.
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Genetically predicted values for thyrotropin levels within the BioVU eMERGE EHR data set were computed using weighted genetic risk scores according to the following formula:
where the SNV genotype is coded as 0, 1, or 2 and w i is the β coefficient (representing effect size) from the published thyrotropin GWAS analysis. 3, 4 A combined thyrotropin predictor was created by combining the SNVs from the 2 predictors (international and Icelandic data sets) and using a clumping algorithm to identify a set of the most strongly associated, independent SNVs in low linkage disequilibrium (r 2 <0.2). 21 This final combined predictor comprised 29 SNVs (Table 1) . The proportion of variance in measured thyrotropin levels explained by the thyrotropin genetic predictor was based on the partial correlation between the predicted (using 20 international thyrotropin SNVs) and measured thyrotropin levels, adjusted for age and sex. These analyses used the subset of BioVU individuals with measured thyrotropin.
For the PheWAS analyses, the thyrotropin predictor included 19 of 20 SNVs that passed quality control (rs11624776 was not included owing to high rates of missing values among eMERGE individuals).
3 An association between each PheWAS phenotype and each genetically predicted biomarker (thyrotropin) was performed using multivariable logistic regression, adjusting for 3 principal components, birth decade, sex, eMERGE site, and genotyping platform. The genetically predicted thyrotropin value was standardized to have an SD of 1, so ORs reflect the risk per SD increase in the genetically predicted thyrotropin level. Association analyses used SAS version 9.3 (SAS Institute). To adjust for multiple testing, we applied a strict Bonferroni correction and associations with (P < .05) / (2 × 1318) = approximately 1.89 × 10 −5 were considered significant. The AF association was also tested excluding 9801 individuals with a phecode related to thyroid disease (phecodes 193.*, 194 .*, 226.*, 227.*, 240.*, and 247.*). The AF-thyrotropin association was replicated using summary statistics data for AF from the AFGen consortium. 14 Two independent SNV sets for thyrotropin were used: the international meta-analysis set (n = 20 SNVs) 3 and the Iceland set (n = 24 SNVs). 4 Genome-wide association studies such as AFGen report regression coefficients summarizing the associations between each SNV and a trait (AF for AFGen study) and not the individual-level data. These summarized data comprise the coefficients (β) and standard errors from univariate regression models of the risk factor on each genetic variant (here, association of thyrotropin with each SNV of international or Icelandic thyrotropin polygenic set) and of the outcome on each genetic variant (here, association of AF with each SNV of international or Icelandic thyrotropin polygenic set). Genetic association studies use combinations of genetic variants as instrumental variables to assess whether a risk factor is associated with a disease outcome. An estimate of association for each individual genetic variant and a combined estimate can be obtained by IVWA meta-analysis of these estimates (Figure, B for association between genetically determined thyrotropin levels and AF). Inverse-variance weighted average meta-analysis was performed using the mendelian randomization R package. 22 An association of 2-sided P ≤ .05 was considered significant in the replication data set. To ascertain whether there was an epidemiologic association between measured thyrotropin levels that fall within the normal range, a logistic regression analysis, adjusting for sex and age, was conducted on individuals older than 55 years. Thyrotropin levels were standardized, so OR estimates reflect the change in risk per SD changes in thyrotropin levels.
Results
Using a discovery population of 37 154 North American individuals of European ancestry (19 330 men [52%]) (Table 2) that we have previously shown to be effective for biomarkers discovery and characterization, 10 we generated a weighted polygenic risk score using SNVs weights from a published international GWAS meta-analysis of thyrotropin based on data of individuals with euthyroid of European ancestry (Table 1) . 3 For each individual, we computed the expected thyrotropin level based on the polygenic risk score. In a subset of 6797 individuals with thyrotropin measurements and without thyroid disease, the estimated additive thyrotropin heritability was 0.31 ± 0.07. The polygenic predictor accounted for 5.8% of 4 The x-axis is the SD change in thyrotropin levels per copy of the reference allele and the y-axis is the change in the log(odds-ratio) of AF risk. The horizontal and vertical whiskers around each point represent the 95% CI for the thyrotropin and AF effect sizes, respectively. The line displays the results of an inverse-variance weighted average meta-analysis summarizing the association between thyrotropin levels and AF risk. NOS indicates not otherwise specified. 1945 (1935-1955) 1945 (1935-1955) 1945 (1935-1955 −4 ). The 2 thyrotropin risk scores were linearly correlated (r = 0.68) and had similar overall distributions (eFigure 2 in the Supplement). Interestingly, none of the individual SNVs used to build the 2 studied thyrotropin polygenic risk scores was significantly associated with AF (Table 1) . A thyrotropin predictor comprising 29 independent SNVs taken from both international and Icelandic data sets showed similar results (OR, 0.90; 95% CI, 0.84-0.97; P = .006) (eFigure1BintheSupplement). To ascertain whether there was a similar epidemiologic association, we examined whether AF was associated with directly measured thyrotropin in individuals without diagnosed thyroid diseases and thyrotropin levels that fell within the normal range. Among individuals older than 55 years, there was an inverse association between thyrotropin and AF (OR, 0.91 per SD change in thyrotropin levels; 95% CI, 0.83-0.99; P = .04).
Discussion
Atrial fibrillation is the most common arrhythmia worldwide with increasing frequency noted with age. 23 Atrial fibrillation affects more than 33 million people worldwide and progressive increases in overall burden, incidence, prevalence, and AF- This association between AF and thyrotropin genetic risk scores persisted even after we repeated the analyses excluding individuals with a diagnosis of thyroid disease, indicating that among individuals not meeting clinical thresholds for diagnosis, variation in genetically determined thyrotropin levels predispose to AF risk. We were also able to recapitulate the AF association using directly measured thyrotropin levels that fell within the normal ranges. Thus, the clinical decision to treat subclinical thyroid disease should incorporate the risk for AF, as antithyroid medications to treat hyperthyroidism may reduce AF risk and thyroid hormone replacement for hypothyroidism may increase AF risk. Interestingly, it has also been shown recently that thyrotropin may have direct electrophysiological effects in rat ventricular myocytes, 30 although the precise mechanisms for the association are not well defined. This study also shows the power of PheWAS to associate clinically relevant candidate diagnoses with biomarker variation. Genetic-based association approaches used in PheWAS are effective because heritable genetic variation represents a lifelong exposure to disease risk. Thus, even modest genetic perturbations in homeostatic levels of a causative biomarker may be detectable given the long duration of exposure. Moreover, the AF meta-analysis, also known as mendelian randomization, avoids some of the limitations of observational studies. In mendelian randomization, since genotypes are not affected by disease status, any reverse causation bias should be avoided. These analyses also highlight the use of coupling polygenic predictors, which better estimate genetic risk as compared with individual SNVs, 31 with PheWAS to enable virtual biomarker studies whereby a biomarker is measured in 1 population and then imputed into and evaluated in a larger, more deeply phenotyped population. Such an approach can vastly increase sample sizes and the number of diseases that can be evaluated for a given biomarker. The use of polygenic predictors also increases power. As an example, while no single SNV has been associated with high effect size explaining druginduced QT prolongation or torsade de pointes in GWAS studies, 32 induced QT prolongation and was a significant predictor of drug-induced torsade de pointes.
Limitations
There are limitations to this study. Phenome-wide association study phenotypes are derived from EHR billing codes and may be underascertained or false positives, which can attenuate the strength of PheWAS associations but also result in missed diagnoses of overt thyroid disease. While the positive predictive value of the AF phenotype was high, we validated the association in an independent, well-adjudicated data set to ensure the reproducibility of our discovery analyses. Some individuals may have been taking medications such as thyroid hormone replacement, which could bias or attenuate results; however, the strength of the association was preserved even after individuals with diagnosed thyroid disorders were dropped from the analysis. The SNVs used in the thyrotropin predictors in the study and replication populations were derived predominantly from individuals of European ancestry. Development and validation of predictors in other ancestries are needed to validate the robustness of the findings in these groups. The finding of an association even in the absence of overt thyroid disease reinforces the potential role for genetically determined variation in thyroid function within a physiologically accepted normal range as a risk factor for this increasingly common arrhythmia. Further prospective studies are required to assess whether thyrotropin polygenic predictors increase the predictive accuracy in AF risk assessment. We considered examining the association between FT 4 or FT 3 and AF, but existing published data did not allow us to construct robust genetic predictors. Studies examining the relationship between genetically determined levels of these hormones and AF risk will be informative to more fully characterize how genetic regulation of the thyroid hormone endocrine axis affects AF risk.
Conclusions
Applying a genetic predictor of thyrotropin levels to an EHR cohort (n = 37 154) identified expected associations with thyroid disorders as well as a significant inverse association with AF, even after dropping cases of overt thyroid disease. This finding was replicated in an AF GWAS study (17 931 AF cases and 115 142 controls) and epidemiologically using directly measured thyrotropin levels and suggests a role for genetically determined variation in thyroid function within a physiologically accepted normal range as a risk factor for this increasingly common arrhythmia. 
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